MORGES, Switzerland, July 20, 2026
Spectrum Dynamics Medical has announced the launch of the All-Energy Enhancement for its FDA-cleared, CE-marked VERITON-CT 400 Series, marking a major advancement in digital SPECT/CT imaging for precision medicine, theranostics, and nuclear medicine. The latest enhancement enables clinicians to image low-, medium-, and high-energy radioisotopes using a single digital platform while maintaining the simplicity of the system’s single-collimator design. The technology has already completed its first customer clinical experience at Florida Theranostics in Jupiter, Florida, where physicians successfully evaluated multiple clinically important radioisotopes, including Technetium-99m (Tc-99m), Iodine-123 (I-123), Iodine-131 (I-131), and Lutetium-177 (Lu-177). Designed to improve image sensitivity, precision, spatial resolution, and quantitative imaging capabilities, the upgraded platform addresses the growing demand for advanced imaging solutions supporting the expanding use of radiopharmaceuticals and targeted cancer therapies while preserving fast scan times and streamlined clinical workflows.
All-Energy Digital SPECT/CT Supports Next-Generation Theranostics
The VERITON-CT 400 Series All-Energy Enhancement represents an important technological breakthrough by enabling comprehensive imaging across virtually the entire range of clinically available photon energies without requiring clinicians to change collimators. Built on Spectrum Dynamics’ proprietary 360-degree digital CZT detector technology, the upgraded system integrates advanced digital detection, image reconstruction, quantitative processing, and workflow optimization into a unified imaging platform. This innovation allows healthcare providers to perform high-quality imaging for oncology, cardiology, neurology, general nuclear medicine, and theranostics using a single system capable of accommodating both current and emerging radiopharmaceuticals. As precision oncology continues to expand through targeted radionuclide therapies, the ability to accurately visualize multiple therapeutic isotopes on one platform significantly improves workflow efficiency while enhancing diagnostic confidence and treatment planning. The All-Energy Enhancement is available for both new VERITON-CT 400 installations and as an upgrade for existing systems, extending the platform’s value across healthcare institutions worldwide.
Florida Theranostics Demonstrates Early Clinical Success
The first real-world clinical evaluation of the enhanced VERITON-CT 400 Series was completed at Florida Theranostics, where Dr. Ashok Muthu Krishnan and his clinical team assessed the platform across several important diagnostic and therapeutic imaging applications. Early experience included whole-body I-131 imaging, Lutetium-177 theranostic imaging, bone imaging, and dopamine transporter studies, demonstrating notable improvements in anatomical clarity, image resolution, quantification accuracy, and overall scan quality compared with previous-generation systems. Importantly, these improvements were achieved while preserving the operational simplicity and efficiency of the original VERITON-CT single-collimator architecture. The successful clinical implementation provides valuable evidence supporting the system’s ability to meet the evolving imaging demands associated with targeted radionuclide therapies, personalized treatment planning, and quantitative molecular imaging. During the initial commercial rollout, Spectrum Dynamics Medical will continue collaborating with leading clinical institutions to optimize imaging protocols, refine workflows, and further expand clinical evidence supporting the technology.
Advertisement
Spectrum Dynamics Advances the Future of Precision Imaging
The introduction of the All-Energy Enhancement reinforces Spectrum Dynamics Medical’s long-standing leadership in transforming conventional SPECT imaging into fully digital, quantitative imaging solutions. Since introducing the world’s first digital cardiac SPECT system, the company has consistently advanced innovations that improve diagnostic accuracy, workflow efficiency, and clinical versatility. The enhanced VERITON-CT 400 Series extends this vision by creating a future-ready imaging platform capable of supporting the rapidly expanding field of precision medicine and theranostics. With regulatory clearances already established through the U.S. FDA, European CE Mark, and Health Canada, Spectrum Dynamics plans broader commercial availability during late Q4 2026, while accepting customer orders immediately. As molecular imaging continues to play an increasingly important role in personalized healthcare, the VERITON-CT 400 Series positions healthcare providers to deliver more accurate diagnosis, improved treatment monitoring, and enhanced patient care across multiple disease areas using a single comprehensive digital imaging platform.
Source: Spectrum Dynamics Medical press release
